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MT4-MMP expression in breast adenocarcinoma stimulates tumor growth and metastatic 
spreading to the lung. However whether these pro-tumorigenic and pro-metastatic effects of 
MT4-MMP are related to a proteolytic action is not known yet. Through site directed 
mutagenesis MT4-MMP has been inactivated in cancer cells through Glutamic acid 249 
substitution by Alanine in the active site. Active MT4-MMP triggered an angiogenic switch at 
day 7 after tumor implantation and drastically accelerated subcutaneous tumor growth as well 
as lung colonization in RAG -/- mice. All these effects were abrogated upon MT4-MMP 
inactivation. In sharp contrast to most MMPs being primarily of stromal origin, we provide 
evidence that tumor-derived MT4-MMP, but not host-derived MT4-MMP contributes to 
angiogenesis. A genetic approach using MT4-MMP-deficient mice revealed that the status of 
MT4-MMP produced by host cells did not affect the angiogenic response. Despite of this 
tumor intrinsic feature, to exert its tumor promoting effect, MT4-MMP requires a permissive 
microenvironment. Indeed, tumor-derived MT4-MMP failed to circumvent the lack of an host 
angio-promoting factor such as plasminogen activator inhibitor (PAI-1). Overall, our study 
demonstrates the key contribution of MT4-MMP catalytic activity in the tumor compartment, 
at the interface with host cells. It identifies MT4-MMP as a key intrinsic tumor cell 
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Tumor growth and metastatic dissemination are associated with an important tissue 
remodeling that requires different proteases. Matrix metalloproteases (MMPs) are zinc-
dependent endopeptidases involved in physiological and pathological extracellular matrix 
remodeling and in cell function regulation 1. Their roles in tumor growth, angiogenesis and 
metastasis are now well documented 1. This protease family includes secreted/soluble (MMP) 
or membrane type-MMPs (MT-MMP) that are anchored to the cell surface through 
transmembrane domain or glycosylphosphatidylinositol (GPI) linker 2. The most studied cell 
surface-associated MMP is MT1-MMP that has been originally identified as an MMP2 
activator 3, that regulates different cell functions including the glycolytic activity of tumor 
cells. It can also directly induce intracellular responses by controlling signal transduction 
through interaction with cell surface receptors 4.  The MT1-MMP driven intracellular 
signaling regulation seems to be, dependent or independent on its catalytic functions. In this 
context, it is worth mentioning that MT1-MMP participates in ERK1/2 pathway activation 
during cell migration in a non-catalytic manner after TIMP-2 binding 5-7.  
Membrane-type 4 MMP (MT4-MMP, also known as MMP-17) is a member of the 
GPI-anchored MT-MMP subgroup that is structurally and functionally distant from other MT-
MMPs. MT4-MMP was originally cloned form a human carcinoma cDNA library 8, 9 and its 
mRNA expression was detected in brain, spleen, uterus, ovary and leukocytes in both human 
and mousse tissues 9-14. Recently, several reports have provided information on MT4-MMP 
function in physiological conditions. MT4-MMP deficient mice develop normal and show no 
abnormalities compared to wild-type mice 14, suggesting that MT4-MMP is not requested for 
normal development in survival. However, a recent study reported that Mt4-mmp-/- mice 
have abnormal diminished thirst that could be a result of dysfunction in thirst regulation in the 
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brain 15. MT4-MMP seems to contribute to the control of cartilage aggrecan integrity in vitro 
and in vivo by its capacity to activate ADAMTS-4 through C-terminal domain processing 16. 
The ability of MT4-MMP to form a complex with ADAMTS4 recently evidenced by co-
immunoprecipitation further support this concept 17. Accordingly, genetic deletion of MT4-
MMP protects mice against IL-1β-induced loss of articular glycosaminoglycans, reinforcing 
the role of MT4-MMP in agreccan proteolysis in vivo 18. On the focus of the present study is 
the role of MT4-MMP’s catalytic activity in tumor progression. 
Previously, we demonstrated that MT4-MMP is localized in cancer cells, but not in 
stromal compartment of human breast cancer 19. MT4-MMP overexpression accelerates the in 
vivo growth and promotes the metastatic dissemination of breast cancer cells through tumor 
vessel architecture alteration 19, 20. In line with these data, MT4-MMP plays a significant role 
in hypoxia-mediated metastasis and is also an important prognostic indicator in patients with 
head and neck cancer 21. In comparison with the abundant information currently available on 
other MT-MMPs, MT4-MMP mechanisms of action in cancer remain to be established. In 
contrast to MT1-MMP, MT4-MMP does not cleave collagens, it is a poor pro-MMP2 
activator and has a restricted substrate repertoire including pro-TNF-α, α2-macroglobulin 22, 
low density lipoprotein receptor related protein (LRP)23 and aggrecanase (ADAMTS-4) 18.  
Whether the pro-metastatic effect of MT4-MMP relies on its catalytic activity is still 
not yet known. In this report, we addressed this important issue by evaluating the effect of 
overexpression of MT4-MMP catalytically-inactive mutant, on in vitro and in vivo 
angiogenesis, tumor growth and lung metastases. We investigated MT4-MMP functions in 
physiological and pathological angiogenesis in a non permissive environment. We provide 
evidence that MT4-MMP triggers angiogenic switch through its catalytic activity in a 
permissive host environment favorable for tumor progression.  
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Materials and methods 
Cell Culture 
Human breast cancer MDA-MB-231 cells were obtained from the American Type 
Culture Collection (Manassas, VA) and HEK-293T cells were purchased from Thermo 
Scientific-Open Biosystems (Wilmington, DE). Cells were grown as described previously 19.   
Inactivation of the MT4-MMP and cell  transfection  
Inert MT4-MMP was produced by site-directed mutagenesis in the highly conserved 
domain HExxHxxGxxH through point mutation of Glutamic acid at position 249 with Glu249 
with Alanin 24-26. The primers used to introduce the mutation were designed as follows: 
Forward, 5’-GCAGTGGCTGTCCACGCGTTTGGCCACGCCATTGGG-3’; reverse, 5’-
CCCAATGGCGTGGCCAAACGCGTGGACAGCCACTGC-3’ (Eurogentec, Seraing, 
Belgium). The mutation and amplification of mutated vector was performed with 
QuikChange® Site-Directed Mutagenesis Kit (Stratagene, USA) according to manufacturer’s 
instructions. Parental MDA-MB-231 and HEK-293T cells were stably transfected by 
electroporation (250 V, 960 AF) with pcDNA3-neo vector containing only the neomycin 
resistance gene (control plasmid, CTR) or with the same plasmid carrying the full-length 
active (MT4) or inert (MT4-E249A) human MT4-MMP cDNA as described previously 19.  
 Preparation of proteins cell extracts, conditioned media and total RNAs 
Conditioned media were prepared by incubating subconfluent cells in 100-mm 
diameter Petri dishes (Falcon, Becton Dickinson, Lincoln Park, NJ) containing 5 ml of serum-
free DMEM for 48 hours. Conditioned media were harvested, clarified and concentrated 20-
fold by centrifugation, using Centricon® YM-30 (Millipore, Chicago, IL). Total protein cell 
extracts were prepared as described previously 19. Total RNAs were extracted from cell 
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monolayer using High Pure RNA isolation kit (Roche) or from tumor tissue using High Pure 
RNA tissue kit (Roche Diagnostic Applied Science, Mannheim, Germany).  
RT-PCR analysis 
RT-PCR was performed as described previously 19. Specific primers for MT4-MMP 
used were: forward, 5-AAGGAGACAGGTACTGGGTGTTC-3; reverse, 5-
TCGCCATCCAGCACTTTCCAGTA-3 (Eurogentec, Seraing, Belgium). Thirty-five cycles 
of amplification were run for 15 seconds at 94°C, 20 seconds at 68°C, and 30 seconds, at 
72°C. For detection of MT1-MMP expression, twenty-two cycles of amplification were 
performed using the following specific primers: forward, 5-
GCATACCCAATGCCCATTGGCCA-3; reverse, 5-CCATTGGGCATCCAGAAGAGAGC-3. 
Western blot analysis 
Samples were separated as described previously 19. Membranes were blocked with 
casein 1%/PBS/tween-20 0.1% and incubated overnight, at 4°C with anti-human MT4-MMP 
antibody (1/1000 dilution) (M3684; Sigma, St. Louis, MO) or anti-human MT1-MMP 
antibody (1/1000) (MAB1767, clone 3G4.2, Millipore- Chemicon) followed by incubation 
with a secondary horseradish peroxidase (HRP)–conjugated anti-rabbit antibody (Cell 
Signaling Technology, Danvers, MA). Signals were detected using an enhanced 
chemiluminescence kit (Perkin-Elmer Life Sciences, Boston, MA). For loading control 
membranes were then stripped and reincubated with an anti-actin antibody ((A2066; Sigma). 
Cell surface biotinylation  
MDA-MB231 cells stably expressing wild type (MT4) or inactive MT4-MMP (MT4-
E249A) were incubated 100 mm dish and cell surface biotinylated with the cell impermeable 
EZlink-sulfo-NHS-biotin (Pierce) as described previously 6 . The cells were then lysed with 
0.5 ml/well of cold lysis buffer on ice. After centrifugation, 500 µg of total protein were 
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incubated with streptavidin-agarose beads (Sigma) overnight at 4°C. The precipitated samples 
were analyzed by western blotting with the MT4-MMP and MT1-MMP antibodies.  
Immunofluorescence 
Cells were incubated on cover slip in 24-well culture plate at 5x104cells/well. After 
incubation for 48h, cells were washed with PBS and fixed for 10 min in 4% PFA at 37°C. 
Cells were either permeabilized or not after incubation for 1 min at room temperature with 
0.1% Triton X-100/PBS. Slides were blocked in in PBS containing 3% bovine serum albumin 
(BSA) solution and incubated with anti-MT4-MMP antibody (1/50) for 1h at room 
temperature. After washing, cells were incubated with a secondary swine anti-rabbit FITC-
conjugated antibody (1/100) (DakoCytomation, Carpinteria, CA, USA) for 1h and  mounted 
with mounting media containing DAPI for nucleus detection (Vectaschield+Dapi, H1200; 
Vector Laboratories, Burlingame, CA, USA). Fluorescence microscopy analysis was realized 
using 40-fold magnification. 
Flow cytometry 
Cells were detached with PBS/EDTA 2.5 mM, counted and 5x105 cells/ml in 
suspension were incubated with anti-MT4-MMP antibody (1/50) in incubation buffer 
(PBS/1% BSA) for 20 minutes at 4°C. After washing, cells were incubated with a secondary 
(1/125) swine anti-rabbit FITC-conjugated antibody (Dako) for 30 minutes, at 4°C. After 
washing steps, stained cells were incubated for 10 min with 10 µl of Via-probe®. Non-
permeabilized cells were analyzed by flow cytometry using 1x104 total events (FACS canto 
II, BD biosciences).  
In vitro BrdU proliferation assay 
In vitro proliferation growth rate was assessed using BrdU kit (11647229001; Roche 
Applied Sciences GmbH, Mannheinm, Germany) according to manufacturer’s 
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recommendations. The assay was conducted after cells incubation (105 cells) in 96-well plate 
for 24, 48 and 72 hours in DMEM medium containing 10 % serum.  
In vivo tumorigenicity 
Subconfluent MDA-MB-231 cells (5 106 cells/ml) were mixed with an equal volume 
of matrigel  and cell suspension (106 cells in 400 µl) was injected subcutaneously (s.c.) into 
recombination activating gene-1 (RAG1-/-) immunodeficient mice at both flanks (5 or 6 mice 
per transfected cells in 3 separated assays) as described previously 27, 28. For some 
experiments, cells were s.c. injected in double transgenic mice PAI-1-/-/RAG1-/- mice or their 
control PAI-1+/+/RAG1-/- mice previously generated 29. Tumor growth was assessed as 
described previously 19. 
Immunohistochemistry 
Slides were autoclaved for 11 min at 126°C in Target Retrieval Solution (DAKO, 
S1699, Glostrup, Denmark) or incubated for 20 minutes at 37°C in trypsin  0,025% (DAKO, 
S2012) for Ki67 and von Willebrand Factor (vWF), respectively. Endogenous peroxidases 
were subsequently blocked by 3% H2O2/H2O for 20 minutes, and nonspecific binding was 
prevented by incubation in PBS/bovine serum albumin 10% (Fraction V, Acros Organics, NJ) 
for 1 hour. Lung and tumor sections (6 µm thick) were incubated with a mouse monoclonal 
anti-human-Ki-67 antibody (1/100) (clone MIB-1, M7240; DAKO) or rabbit polyclonal anti-
von Willebrand Factor (vWF) (1/200) (DAKO, A0082) at room temperature, for 1 hour, 
respectively. Slides were then incubated with a HRP-conjugated secondary antibody and 
counterstained as described previously 19. For proliferation index determination, plug sections 
were double stained with anti-human-Ki-67 and anti-vimentin antibodies. Slides stained with 
Ki-67 antibody were colored with Permanent Red (K0640, Dako). Co-immunostaining with 
vimentin was first performed by blocking endogenous peroxydases and incubation with anti-
vimentin antibody (1:750, diluted in Tris-HCl / Normal Goat Serum) overnight at 4°C, 
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followed by the Post Antibody Blocking (Immunologic, Duiven, Nederlands) for 15 min. 
Finally, poly-HRP-goat anti Mouse/Rabbit/Rat IgG was added for 30 min on the slides which 
were revealed with Vector DAB (SK-4100, Vector Laboratories, Burlingame, CA, USA).  
For quantitative measurement of human Ki-67 staining related to human vimentin staining, a 
specific automatic computer-assisted image analysis was applied on sections by using 
Application Software (3.2). In RGB images, human vimentin appeared in red and Ki-67 in 
brown colors. After separation of those components, red and brown images were binarized 
automatically and these binarized images were used to determine the colocalization of 
vimentin and ki-67 using a logical operator (AND). The colocalization area density for each 
condition was finally determined. 
Matrigel plug assays  
Mt4-mmp-/- mice (previously generated by Motoharu Seiki’s laboratory, University of 
Tokyo, Japan) 14 were subjected to matrigel plug assay.  Matrigel (500 µl) supplemented with 
25µl/ml of bFGF (R&D, Minneapolis, USA) and 25000 units of heparin (LEO pharma, 
Zaventem, Belgium) was s.c. injected in both flanks of mice Mt4-mmp-/- mice. Plugs were 
resected after 7 days prior to quantification of hemoglobin content using Drabkin’s reagent 
according to the manufacturer’s instructions (Sigma-Aldrich, St Louis, USA). For some 
experiments, we have adapted matrigel plug assay through substitution of bFGF and heparin 
with cells (106) transfected with active (MT4) or inert MT4-MMP cDNA (MT4-E249A). 
Cells mixed in matrigel were injected s.c. in RAG1-/- mice and 7 days later, hemoglobin 
concentration was measured with Drabkin’s reagent. For both assays, the amount of 
hemoglobin was normalized to the weight of lyophilized matrigel plug containing or not 
tumor cells. The data are from three independent experiments.  
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Aortic ring assay 
Aortic explants from Mt4-mmp-/- mice (n=6) or Mt4-mmp +/+ mice (n=6)  were 
incubated for 6 days at 37°C according to the procedure previously described 30. Images were 
captured on Zeiss microscope at day 6. A total number of 18 explants were tested by using 
three aortic explants of each mouse. Computerized quantification of vessel density and 
branching was performed as previously described 31. 
Corneal whole mounts 
Corneal lymphangiogenesis was assessed in Mt4-mmp -/- (n=6; number of cornea=12)   
and Mt4-mmp +/+ mice (n=6; number of cornea=12) induced by thermal cauterization of the 
central cornea with an ophthalmic cautery (OPTEMP II V, Alcon Surgical, FortWorth, USA). 
Seven days after cauterization, corneas were resected and blood vessels were highlighted after 
over-night incubation with rat anti-mouse CD31 monoclonal antibody (Pharmingen, 01951D). 
Corneas were washed with PBS and incubated 2 hours incubation at room temperature with 
Alexa Fluor 488 conjugated rabbit anti-goat antibody (Molecular Probes). Computerized 
quantification of vessel density was performed according to Blacher et al. 32. Results are 
expressed as normalized vessel density (Ni) plotted as function of the distance from the 
external border of the cornea.  
Statistical analysis 
We assessed statistical differences between different experimental groups using Mann-
Whitney test. P-value < 0.05 (*) was considered as significant. Statistical analyses were 
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The inactivation of MT4-MMP activity does not influence its shedding from the cell surface 
To test the importance of the MT4-MMP catalytic activity on cell based system in 
vitro and on tumor malignancy in vivo, we have generated a mutated inactive form of the 
enzyme. Using a similar approach previously described to generate inactive MT1-MMP 
(MT1-E240A) 33, the highly conserved Glutamic acid-249 (E249) was replaced by Alanine in 
the catalytic domain of MT4-MMP by site-directed mutagenesis. Human breast 
adenocarcioma MDA-MB231 cells were stably transfected with an empty vector 
(pcDNA3neo or “CTR”) or a vector containing either the active full length MT4-MMP cDNA 
(named herein “MT4”) 19 or mutant inactive cDNA (“MT4-E249A”). MT4-MMP mRNA 
expression was analyzed by RT-PCR and protein production was assessed by western blotting 
performed on total cell lysates (Figure 1A). No MT4-MMP expression was detected in control 
cells, whereas mRNA and proteins MT4-MMP and MT4-E249A were found in cells 
transfected with vector containing MT4-MMP cDNA mutated or not (Figure 1A). MT4-MMP 
being a GPI-anchored membrane type MMP, its distribution at the cell surface and in the 
cytoplasm was examined by immunofluorescence on adherent non-permeabilized and 
permeabilized cells, respectively (Figure 1B). Both cells transfected with MT4-MMP or 
MT4-E249A form showed a specific cell surface and cytoplasmic staining, whereas no 
staining was detected in control cells. FACS analysis on non-permeabilized cells revealed that 
the percentage of MT4-MMP captured by flow cytometry ranged from 15 to 20% in both 
MT4-E249A and MT4-MMP expressing cells (Figure 1C). Because an important amount of 
the enzyme could be shed into the medium, degraded or internalized in the cell, data from 
flow cytometry analysis does not reflect the whole levels of MT4-MMP in cells.  
To assess cell surface-associated MT4-MMP, cells were surface biotinylated. Biotin-
labeled proteins, including MT4-MMP, were precipitated using streptavidin-agarose beads. 
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The levels of MT4-MMP in the precipitates were determined by Western blotting (Figure 
1D).  MT4-MMP was not detected in control cells.  In cells over-expressing MT4-MMP, the 
amount of membrane-associated MT4-MMP was significantly higher for the intact than for 
the mutated MT4-E249A form. These data are in line with those obtained with total cell 
lysates and through flow cytometry analysis. Since mRNA levels were similar in all cell 
types, differences at protein levels on the cell surface could rely on posttranslational 
regulation such as for instances protein shedding or internalization. We checked that MT1-
MMP expression levels are not affected at the cell surface of MT4-MMP, MT4-E249A and 
control cells (Figure 1D). The previous demonstration of MT4-MMP shedding from MDCK 
and CHO cells 16, 34 prompted us to evaluate the levels of soluble MT4-MMP in medium 
conditioned by transfected cells (Figure 1E). Whereas no MT4-MMP species was detected in 
control cells, significant amounts of a soluble MT4-MMP form of around 50 kDa were found 
in medium conditioned by both active and inactive mutant MT4-MMP expressing cells 
(Figure 1E). Consistently with a previous study 34, these data suggest that MT4-MMP did not 
shed itself from the cell surface through its catalytic activity. However, a drastic difference 
was observed in soluble MT4-MMP processing following its release from the surface of cells 
expressing active or inactive enzymatic form. Indeed, a 37 kDa fragment and a doublet of 
degradation products were abundantly detected in the media of cells overexpressing active 
MT4-MMP, but not in that of cells overexpressing inactive MT4-E249A (Figure 1E). This 37 
kDa MT4-MMP species is thus likely generated by active MT4-MMP autocleavage that could 
be a new regulatory mechanism of the proteolytic activity of this MT-MMP. To check 
whether MT1-MMP expression is affected in cell transfected with MT4-MMP, and whether 
this protease may be responsible for MT4-MMP shedding and processing, we have analyzed 
the level of MT1-MMP by RT-PCR and western blotting on total cell lysates (Figure 1A). 
MT1-MMP mRNA expression was not affected significantly by the expression of MT4-MMP 
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or its mutant inactive form. However, a slight increase in MT1-MMP at protein level was 
detected in MT4-E249A cells, suggesting that MT1-MMP is not responsible for the 
generation of the 37 kDa form of MT4-MMP.  
 
The in vivo pro-tumorigenic and pro-metastatic effects of MT4-MMP are dependent on its 
catalytic activity 
To investigate the effect of MT4-MMP catalytic activity on in vitro proliferation, we 
first characterized and evaluated the proliferative potential of transfected cells cultured on 
plastic dish through BrDU incorporation (Figure 2A). No difference was seen in the 
proliferation rate of the different cells generated. In agreement with our previous 
observations, MT4-MMP expression did affect neither cell proliferation nor pro-MMP2 
activation in vitro 19.  
To determine whether MT4-MMP catalytic activity is required for in vivo tumor 
growth and metastatic dissemination into lungs, cells were s.c. injected into RAG1-/- mice and 
tumor volumes were measured for 45 days. The production of active MT4-MMP form 
stimulated drastically tumor growth (Figure 2B). Interestingly, MT4-E249A form was 
inefficient in promoting tumor growth revealing that the pro-tumorigenic effect of this MMP 
is dependent to its catalytic activity. In fact, MT4-E249 tumors were smaller than either MT4 
or control tumors, suggesting a possible suppressor effect of the mutant inactive form of 
MT4-MMP. The expression of MT4-MMP and MT1-MMP were measured in tumors at day 
45 by RT-PCR analysis (Figure 2C). As expected, MT4-MMP mRNAs were detected at 
similar levels in both MT4 and MT4-E249A tumors at day 45, but not in control tumors. 
MT1-MMP mRNA expression was equivalent in all tumors suggesting that the tumor 
promoting effect of active MT4-MMP is not associated with changes in MT1-MMP 
expression in vivo. The impact on metastasis was next evaluated by immunohistochemical 
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analysis of lungs and lymph nodes samples (Figure 2D). The inactivation of MT4-MMP 
catalytic function reduced lung metastasis to similar level of control cells (Figure 2D). 
However, lymph node metastases were not affected by control cells or cells expressing either 
active or inactive form of MT4-MMP (data not shown). These results are in line with our 
previous report 20, confirming that this protease induces preferentially hematogenous 
metastatic dissemination rather than lymphatic spreading. All together, our data demonstrate 
that MT4-MMP-driven metastatic effects depend on its proteolytic activity and that targeting 
the active site of the enzyme would be of interest to limit tumor metastasis of breast 
carcinoma expressing MT4-MMP.  
 
The proteolytic activity of MT4-MMP is required to trigger the tumor angiogenic switch in 
a permissive tumor environment. 
Our previous finding demonstrated that MT4-MMP expressing tumors have large and 
bloody vessels 20. This prompted us to investigate the onset of angiogenic response induced 
by the different tumor cells generated. With this aim, we have used a modified matrigel plug 
assay in which matrigel supplemented with cancer cells were s.c. injected into RAG1-/- mice. 
After 7 days, hemoglobin content was determined in whole plugs (Figure 3A, lower panel). 
MDA-MB231 cells overexpressing active MT4-MMP induced an early angiogenic response 
at least twice higher than that induced by control cells. In sharp contrast, in the absence of 
enzyme activity, the pro-angiogenic effect of MT4-MMP was similar to control tumors. 
Vessel properties and architecture were analyzed by immunohistochemistry staining with von 
Willebrand Factor on matrigel plug sections at day 7 (Figure 3A, top panel). Accordingly, an 
increase in vessels density is shown in MT4 tumors but not in control or MT4-E249A tumors. 
The large vessels detected in MT4 tumors show the presence of red blood cells without 
hemorrhage or sign of leakage, excluding any interference with hemoglobin measurement in 
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the matrigel plugs. To check whether the angiogenic effect of MT4-MMP expressing cells 
might be ascribed to an effect on proliferation, plugs collected at day 7 were double-
immunostained with human Ki-67 for proliferating cells and human vimentin for cancer cells 
(Figure 3B). A computerized method based on image binerization was used to determine the 
density of proliferative cancer cells (Ki-67 and human vimentin positive). No significant 
difference of proliferation rate was observed in matrigel plugs containing the different cell 
types (Figure 3B). In addition, cell density was similar in all plugs (cell number per field of 
view = 309±45 for MT4-MMP plugs, 297±47 for MT4-E249A plugs and 302±53 for control 
plugs.  These data demonstrate that the angiogenic switch induced early at day 7 by MT4-
MMP does not rely on a modulation of cell proliferation and cell density in the plugs.  
Moreover, another cell line HEK-293T stably transfected with MT4-MMP, MT4-
E249A or control cells showed the same results as MDA-MB231 cells (Figure 3C and D). 
MT4-MMP expression in HEK-293T cells induced an early angiogenic switch, whereas the 
inactive form and control cells were unable to induce tumor angiogenesis in vivo (Figure 3C). 
This MT4-MMP-driven angiogenic switch can contribute to the fast growth of tumors, as well 
as to their metastatic dissemination. The pro-angiogenic effect of MT4-MMP might require 
appropriate interactions occurring between host cells and tumor cells expressing the enzyme 
at their cell surface. To evaluate the importance of tumor-host interface in MT4-MMP 
functions, cells expressing active or inactive MT4-MMP were s.c. implanted into an host 
environment poorly permissive to angiogenesis. With this aim, we used immunodeficient 
RAG-1-/- mice in which Plasminogen-Activator Inhibitor-1 (PAI-1) gene has been deleted 29. 
There is a large body of evidences demonstrating that PAI-1 is an important host determinant 
regulating the angiogenic switch in early steps of cancer progression 35. As anticipated, active 
MT4-MMP significantly accelerated the growth of tumors induced by cell injection into PAI-
1+/+ /RAG1-/- mice (Figure 4). In sharp contrast, slowly growing tumors were observed in PAI-
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1+/+ /RAG1-/- mice xenografted with cells expressing inactive MT4-MMP (MT4-E249A) 
(Figure 4). At different time points, tumor volumes were reduced in PAI-/-/RAG-/- mice 
inoculated either with MT4-MMP or control tumors compared to PAI+/+/RAG-/- mice. Both 
wild type and PAI-1 deficient mice developed small tumors after inoculation of cells 
expressing inactive mutant form MT4-E249A. There was no significant difference in tumor 
volumes between MT4, MT4-E249A and control cells in PAI-1-/-/RAG1-/- mice. Thus, MT4-
MMP-driven tumor promotion was completely abolished in the absence of host PAI-1. These 
data suggest that MT4-MMP is an important factor for cancer malignancy where the 
microenvironment is permissive for tumor development.   
 
MT4-MMP is a selective tumor cell determinant of cancer progression 
We next wonder whether MT4-MMP produced by host cells could also affect 
angiogenesis and tumor growth in vivo. We have explored the angiogenic responses elicited in 
the absence of host MT4-MMP by applying several in vitro and in vivo models into recently 
generated Mt4-mmp-/- and Mt4-mmp+/+ mice 14 (Figure 5). Despite MT4-MMP production by 
vascular cells in the aorta 14, in the aortic ring assay (Figure 5A), no difference was found in 
vessel sprouting or branching from explants isolated either from Mt4-mmp-/- or Mt4-mmp+/+ 
mice, computerized quantification of vessel density did not show any difference (Figure 5B). 
Similarly, identical angiogenesis was evidenced in the matrigel plug assay applied to mutant 
and WT mice (Figure 5C). These data suggest that MT4-MMP expression by host cells did 
not affect angiogenesis in vivo. We next extended our exploration to angiogenic process 
associated with tissue injury repair. In the corneal assay induced by thermal cauterization, 
blood vessels sprouting from the limb and migrating into the cornea center were visualized by 
immunostaining of whole mounted cornea with an anti CD31 antibody (Figure 5D). Similar 
decrease of vessel density from corneal periphery to the center of lesion was seen in the two 
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mice genotypes (Figure 5E). All together, these data demonstrate that MT4-MMP expression 
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Although MT4-MMP has been shown to induce tumor growth and metastasis, the 
extent to which the effect is mediated through its proteolytic activity has not been examined 
yet. In this study, we evaluated the pro-angiogenic, the pro-metastatic and pro-tumorigenic 
effects of active site defective MT4-MMP mutant. We first generated stable adenocacinoma 
cells expressing the inactive form of MT4-MMP and characterized its production, processing 
and shedding in vitro. The shedding of MT4-MMP from cell surface was not inhibited by 
inactivating mutation of the enzyme, demonstrating that MT4-MMP did not shed itself from 
cell surface. However, the form shed in the conditioned media was cleaved and generated a 
stable 37 kDa form in MT4-MMP expressing cells but not in cells producing the inert 
enzymatic form. These data suggest the presence of an autoproteolytic activity of the enzyme, 
and this provides a new regulatory mechanism of MT4-MMP activity. Similarly, in the case 
of MT1-MMP, a 44 kDa fragment has been reported to result from autolytic shedding of the 
catalytic domain. This inactive 44 kDa MT1-MMP fragment accumulating on the cell surface 
does not interfere with pro-MMP2 activation 36, but regulates collagenolytic activity and cell 
invasion 37. In the case of MT4-MMP, further investigations are required to determine 
whether soluble 37 kDa fragment could display specific functions.  
MMPs are involved in angiogenesis through different mechanisms including at least 
perivascular matrix remodeling, release of angiogenic factors from the ECM or cleavage of 
angiogenic inhibitors 2. MT4-MMP has been linked to tumor growth and metastasis in several 
cancer models. It is induced by hypoxia through HIF1-α and activation of SLUG, a well 
known transcription factor implicated in epithelial-mesenchymal transition (EMT) that 
promotes cancer cell malignant capacity 21. Another mechanism of MT4-MMP relays on the 
induction of vessel enlargement and vessel destabilization that could promote extravasation 
and metastasis 20. Herein, by using functional assays, we demonstrate that MT4-MMP-
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mediated malignancy relied at least on the induction of an early angiogenic switch in both 
MDA-MB231 and HEK-293T tumors that drives the fast growth of tumors and metastatic 
dissemination to the lung. Of interest is our finding that all these malignant phenotypes were 
abrogated in the absence of catalytic activity of the enzyme in vivo. Intriguingly, MT4-E249A 
expressing tumors grew more slowly than control tumors, suggesting a suppressor effect of 
this enzymatically inactive form. Although, MT4-MMP was not detected by RT-PCR and 
western blot analysis in MDA-MB231 cells, the presence of a very thin band after cell surface 
protein enrichment in figure 1D does not exclude the presence of very low amount of 
endogenous MT4-MMP which could be inhibited by MT4-E249A form through a 
competition for substrate. However, one cannot exclude the possibility that MT4-MMP forms 
heterodimers with a yet unknown membrane molecule as suggested in a recent study 38. Thus, 
the inactive MT4-MMP mutant could interfere with such a complex formation resulting in an 
unexpected modulation of tumor growth. Further studies are required in vitro and in vivo to 
address this interesting issue. Indeed, although non-proteolytic function of membrane type-
MMP (MT1-MMP) are emerging 6, 7, the proteolytic activity of MT4-MMP is required in vivo 
for its pro-angiogenic and pro-metastatic effects. 
In contrast to most MMPs being primarily of stromal origin, we provide evidence that 
tumor-derived MT4-MMP, but not host-derived MT4-MMP contributes to angiogenesis. It 
identifies MT4-MMP as a key intrinsic tumor cell determinant that contributes to the 
elaboration of a permissive microenvironment for metastatic dissemination. These data 
clearly demonstrate that tumor-derived active MT4-MMP cannot overcome the absence of an 
angiogenic host determinant such as PAI-1. It was worth addressing this issue since our 
previous work demonstrated that the angiogenic effect of PAI-1 on human cervical and skin 
carcinoma cells was dependent to their intrinsic invasive potential 29. Indeed, the lack of PAI-
1 significantly reduced the incidence of subcutaneous tumors derived from poorly aggressive 
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HaCaT II-4 cells, but not the incidence of tumors derived from the more aggressive HaCaT 
A5-RT3 cells 29. The fact that MT4-MMP expression promotes tumor growth in the presence 
of PAI-1 suggests that this enzyme endows tumor cells with some malignant features in a 
permissive tissue environment, but is not per se sufficient to convert a tumor cells into a fully 
competent malignant cells 39. 
While most MMPs are produced by stromal cells including fibroblasts, endothelial 
cells and inflammatory cells, only a few MMPs are selectively expressed by cancer cells 40. A 
proteolytic-dependent regulation of the angiogenic switch has been attributed to several host-
derived MMPs 41, 42. For instances, MMP9 secreted by host macrophages or neutrophils as a 
key regulators of tumor angiogenesis 43. On the other hand, MT1-MMP produced by 
endothelial cells stimulated angiogenesis in vitro 44, and its deletion in Mt1-mmp-/- mice 
impaired angiogenesis, delayed skeletal development 45 and increased steady-state vascular 
leakage in vivo 46. The concept that cancer cell-specific proteinase contributes to angiogenesis 
within the tumor stroma is supported by a study reporting the capacity of MMP7 to cleave 
connective tissue growth factor (CTGF), a VEGF sequester 47. MT4-MMP is among the very 
few MMPs selectively produced in the tumor compartment, as demonstrated in human breast 
cancer samples 19. To determine whether host-derived MT4-MMP could contribute to 
angiogenesis, we applied to Mt4-mmp-/- mice three powerful models of angiogenesis: the 
aortic ring assay, the matrigel plus assay and, the corneal assay 32, 39, 48. Our data show that 
MT4-MMP expression in host cells did not affect angiogenesis in none of these models. This 
is in line with the absence of apparent phenotype in Mt4-mmp-/- mice 14. In sharp contrast, 
cancer-derived MT4-MMP expression in cancer cells regulated the tumor angiogenic switch 
and promoted tumor growth and hematogenous metastases. Therefore, the localization of 
MT4-MMP in tumor cells is a key determinant for cancer progression. As a possible 
underlying mechanism, this MT4-MMP tumor promoting effect is likely mediated by 
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interference with tumor vessels. Indeed, we previously shed light on the capacity of this 
membrane type protease to induce the detachment of pericytes from endothelial cells leading 
to vessel destabilization and enlargement 4, 20. The present demonstration that cancer-derived 
MT4-MMP is not sufficient to promote cancer progression further supports its key role at the 
tumor-vessel interface. MT4-MMP appears therefore as a key target deserving further 
investigation and worth targeting through antibody-based therapy 49 or chemical compounds 
50. 
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Figure 1. Expression and characterization of inactive form of MT4-MMP in MDA-
MB231 cells. MDA-MB-231 cells stably transfected with empty vector (CTR), MT4-MMP 
cDNA 19 or inactive MT4-MMP cDNA (MT4-E249A). A. RT-PCR analysis of MT4-MMP, 
MT1-MMP mRNA and 28S rRNA (loading control) were performed as described previously 
19. Total cell lysates were analyzed by western blotting with the anti-human MT4-MMP, anti-
MT1-MMP antibody and anti-β-actin antibody for loading control. Each sample is loaded in 
duplicate lane for RT-PCR and western blot analyses.  B. Immunofluorescent detection of 
MT4-MMP on non-permeabilized (top panel) and permeabilized (lower panel) cells cultured 
on coverslips using a fluorescent microscope at 40-fold magnification. C. FACS analysis of 
cells stained with anti-MT4-MMP antibody. D. Detection of MT4-MMP and MT1-MMP 
levels at the cell surface on biotin labeled plasma membrane samples by western blotting to 
MT4-MMP. E. Detection of soluble form of MT4-MMP shed in cell culture media. Data are 
representative of at least two independent experiments.    
 
Figure 2. Inactivation of MT4-MMP in breast carcinoma cells inhibits in vivo tumor 
growth and metastasis. A. Cell proliferation assay of cells cultured on plastic dishes using 
BrdU kit. B. In vivo tumor growth curves of cells transfected with MT4-MMP (MT4), 
inactive MT4-MMP (MT4-E249A) and control cells (CTR) Tumor cells (106) were s.c. 
injected in RAG1 -/- mice and tumor were measured for 45 days as described in materials and 
methods. C. MT4-MMP and MT1-MMP expression levels in tumors at day 45, analyzed by 
RT-PCR using human specific primers as described in materials and methods. D. 
Quantification of lung metastases after immunostaining using human-Ki67 antibody. 
Columns are means of tumor cells counted in 20 microscopic fields of a lung section 
(magnification 20-fold) (n = 5). Data are those of three independent experiments (n = 5). Bars 
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are standard errors. Statistical analysis was performed using Mann-Whitney test with Prism 
5.04 software (GraphPad, San Diego, CA). P-value: * p < 0,05; ** p < 0,01. 
 
Figure 3. MT4-MMP catalytic activity triggers early angiogenic switch. A. Matrigel 
containing MDA-MB231 cells expressing MT4-MMP or its inactive form (MT4-E249A) and 
control cells were s.c. injected into RAG1-/- mice. Immunohistochemistry detection of vessels 
on matrigel plug sections at day 7 after von Willebrand Factor staining (top panel). 
Hemoglobin content was determined after 7 days (left graph below pictures). Values were 
normalized to the weight of lyophilized tumors. Data are those of three independent 
experiments (n = 5). B Immunohistochemistry detection of proliferating cells in matrigel plug 
sections at day 7 after double immunostaining with human Ki-67 antibody (red staining) and 
human vimentin antibody (brown staining)  (top panel). Proliferation index was determining 
the ratio between, the number of proliferating cells (ki-67 positive, brown color) and total 
cancer cells (vimentin positive, red color) (right graph below pictures).  C. Matrigel 
containing HEK-293T cells expressing MT4-MMP (MT4-HECK) or its inactive mutant form 
(MT4-E249A-HEK) and control cells (CTR-HEK) were s.c. injected into RAG1-/- mice. 
Hemoglobin content was determined after 7 days. Values were normalized to the weight of 
lyophilized tumors. Data are those of three independent experiments (n = 5).  Bars are 
standard errors. D. MT4-MMP expression by RT-PCR and western blot analysis on HEK-
293T cells stably transfected with MT4-MMP, MT4-E249A cDNA and control vector. 
Statistical analysis was performed using Mann-Whitney test with Prism 5.04 software 
(GraphPad, San Diego, CA). P-value: * p < 0,05; ** p < 0,01. 
 
Figure 4. Tumor growth of cells expressing MT4-MMP, inactive mutant form MT4-
E249A and control cells in the absence of PAI-1.  RAG1-/- mice deficient for PAI-1 were 
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generated by intercrossing PAI-1-/- mice with RAG1-/- mice 29. Cells were s.c. injected into 
both flanks of PAI-1-/-/RAG -/- mice or PAI-1+/+/RAG -/- mice (n = 5). Tumors were measured 
at day 26, 33 and 41, and mice were sacrificed at day 41. The data are those of three 
independent experiments. Bars are standard errors. Statistical analyses were performed using 
Mann-Whitney test with GraphPad Software (GraphPad, San Diego, CA). P-value: * p < 
0,05; ** p < 0,01 
 
Figure 5. Effect of MT4-MMP produced by host cells on angiogenesis. A. Aorta ring 
assay. Mice aortic explants from Mt4-mmp-/- mice were incubated for 6 days at 37°C. Similar 
angiogenic response was observed in WT mice and Mt4-mmp-/- mice. B. Quantification of 
normalized vessel density (Ni) plotted as function of the distance from the external border of 
the aorta ring. Matrigel plug assay. C. Matrigel supplied with recombinant bFGF was s.c. 
injected in both flanks of mice. Plugs were resected after 7 days prior to quantification of 
hemoglobin content with Drabkin’s reagent as described in Figure 2. D. Corneal assay. 7 days 
after thermal cauterization corneas were resected and whole mounted. Blood vessels were 
highlighted after staining with mouse CD31 and detected with Alexa Fluor 488-conjugated 
secondary antibody and fluorescent microscopy analysis. E. Computerized quantification of 
normalized vessel density (Ni) plotted as a function of distance from the external border of 
the cornea 32.  
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